{
  "id": "myocarditis",
  "title": "Myocarditis",
  "lang": "en",
  "source_lang": "en",
  "summary": "Myocarditis is inflammation of heart muscle that can cause chest pain, impaired pumping, dangerous arrhythmias, or sudden death.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "Inflammatory disease of the myocardium"
  ],
  "generated_at": "2026-11-06",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/myocarditis/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/myocarditis/",
      "json": "https://aiwiki.page/zh/myocarditis.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Myocarditis is inflammation of the myocardium, the muscular layer of the heart. It encompasses several diseases in which infection, immune-mediated injury, or other insults damage heart muscle cells and provoke an inflammatory response. Its manifestations range from clinically silent abnormalities to chest pain, heart failure, life-threatening rhythm disturbances, and cardiogenic shock. Myocarditis is distinct from myocardial infarction, which usually results from interruption of coronary blood flow, although the two conditions can initially look similar.\n\nThe importance of myocarditis lies partly in its unpredictability. Many patients recover, sometimes completely, while others develop persistent ventricular dysfunction, recurrent inflammation, or an electrically unstable scar. Diagnosis requires the integration of symptoms, blood tests, electrical recordings, cardiac imaging, and, in selected cases, tissue examination. Different causes and pathological forms have different implications for treatment, so identifying inflammation is only one part of defining the disease."
    },
    {
      "heading": "Definition, disease boundaries, and epidemiology",
      "text": "The myocardium contains contractile muscle cells, blood vessels, connective tissue, and resident immune cells. In myocarditis, inflammatory cells enter or accumulate within this tissue, usually with evidence of associated muscle-cell injury. The term describes a pathological process rather than a single cause. A recent respiratory infection, exposure to a particular drug, or an accompanying autoimmune disorder can provide context, but none alone establishes that myocardial inflammation is present.\n\nMyocarditis overlaps with pericarditis, inflammation of the sac surrounding the heart. The term myopericarditis commonly describes a predominantly pericardial syndrome with evidence of myocardial injury but without newly impaired ventricular function. Perimyocarditis is often used when myocardial involvement and ventricular dysfunction predominate, although terminology varies among clinical frameworks. These distinctions matter because pericardial pain, myocardial pump failure, and ventricular arrhythmias represent different consequences of inflammation and do not necessarily require identical management.\n\nMyocarditis also intersects with cardiomyopathy, a group of disorders affecting heart muscle structure and function. Inflammatory cardiomyopathy denotes myocarditis associated with cardiac dysfunction. Dilated cardiomyopathy can follow an inflammatory episode, but ventricular enlargement and weakness do not themselves establish ongoing inflammation. Conversely, myocarditis may occur while chamber dimensions and the left ventricular ejection fraction remain normal.\n\nIts true incidence is difficult to measure. Mild cases may never reach medical attention, while severe cases are more likely to undergo advanced imaging or biopsy. Administrative databases depend on diagnostic coding, and autopsy studies examine selected populations rather than representative samples of living people. Published estimates therefore differ according to case definition, geography, age, and access to diagnostic technology. A rise in recorded cases can reflect improved recognition as well as a genuine change in disease frequency.\n\nMyocarditis occurs at all ages, from infancy to late adulthood. Many clinically recognized acute cases occur in younger adults, and men are overrepresented in numerous cohorts. Sex differences may reflect hormonal, immunological, behavioral, and ascertainment factors rather than one established mechanism. Pediatric myocarditis can present with feeding difficulty, respiratory distress, or shock instead of recognizable chest pain. In older adults, coexisting coronary artery disease and other illnesses can complicate interpretation. Because patient populations differ substantially, an outcome estimate derived from hospitalized patients with shock cannot be applied directly to people with mild, uncomplicated disease."
    },
    {
      "heading": "Infectious, immune-mediated, and exposure-related causes",
      "text": "Infectious agents associated with myocarditis include viruses, bacteria, parasites, and, less commonly, fungi. Enteroviruses, particularly coxsackie B viruses, historically occupied a central place in clinical and experimental research. Adenoviruses, human herpesvirus 6, and parvovirus B19 have also been detected in myocardial samples. The distribution of reported agents has changed with geography, laboratory methods, and the populations studied. Detection of viral genetic material is not always proof that the organism caused the inflammation: some viral sequences can persist without clearly established pathogenic activity.\n\nSeveral infections have distinctive cardiac associations. Diphtheria toxin can injure myocardial cells and disrupt electrical conduction. Borrelia burgdorferi, the principal cause of Lyme disease, can produce carditis characterized especially by atrioventricular conduction abnormalities. Trypanosoma cruzi causes Chagas disease, in which acute infection and long-term inflammatory injury can lead to conduction disease, ventricular arrhythmias, aneurysms, and cardiomyopathy. Chagas cardiomyopathy is not simply an acute viral-like syndrome; it reflects a prolonged interaction among infection, immunity, and tissue damage.\n\nMyocarditis also occurs with systemic autoimmune diseases, including systemic lupus erythematosus and some forms of vasculitis. Cardiac sarcoidosis is a granulomatous inflammatory disease that overlaps with the myocarditis spectrum but has its own diagnostic and treatment framework. Eosinophilic myocardial inflammation may accompany drug hypersensitivity, parasitic infection, eosinophilic granulomatosis with polyangiitis, or hypereosinophilic syndromes. In some cases, no precipitating cause is identified despite extensive investigation.\n\nMedicines can cause myocarditis through several mechanisms. Clozapine-associated myocarditis is a recognized adverse drug reaction, often occurring early after treatment begins. Cancer treatment with an immune checkpoint inhibitor can remove restraints on immune activation and, rarely, provoke serious myocarditis. This form may coexist with skeletal-muscle inflammation and myasthenia gravis. Direct toxic injury from certain substances can also affect the myocardium, although toxic cardiomyopathy should not automatically be classified as inflammatory myocarditis.\n\nBoth COVID-19 and certain vaccines against it have been associated with myocarditis. The association following mRNA vaccination is best established in adolescent and young adult males, particularly after a second dose, with risk varying by product, dose interval, age, and surveillance system. Many recognized cases have had a short hospital course, but persistent imaging abnormalities can occur. In COVID-19, elevated cardiac injury markers are much more common than confirmed myocarditis: ischemia, critical illness, thrombosis, and stress-related dysfunction are alternative explanations. Comparisons between infection-associated and vaccine-associated risk require matched populations, consistent definitions, and clearly specified time windows."
    },
    {
      "heading": "Cellular injury, immune responses, and remodeling",
      "text": "The biological pathways leading to myocarditis differ by cause, but they converge on injury to heart muscle cells and activation of the immune system. Some viruses can enter susceptible cardiac cells and interfere with cellular machinery. Others may affect vascular or supporting cells, with myocardial injury arising partly through inflammatory signaling or microvascular dysfunction. Direct infection of muscle cells is therefore one possible mechanism, not a requirement for every infectious form.\n\nThe early response involves innate immune recognition of microbial products or molecules released from damaged tissue. These signals activate resident immune cells and recruit circulating leukocytes. Inflammatory mediators alter vascular permeability, contributing to edema within the myocardium. Swelling, disturbed calcium handling, impaired cellular energy production, and contractile-protein dysfunction can reduce pumping ability before widespread permanent cell loss develops. This helps explain why ventricular function can sometimes improve rapidly as acute inflammation resolves.\n\nAdaptive immunity may amplify or prolong the process. T cells can recognize pathogen-derived antigens or antigens from injured cardiac tissue, while antibodies may participate in selected disease mechanisms. Experimental models support roles for molecular mimicry, in which microbial and host structures share immunological features, and for loss of tolerance to cardiac proteins. These mechanisms are not equally established in every human case. An immune response that helps control infection may also contribute to tissue damage, making indiscriminate suppression of immunity biologically problematic.\n\nHealing can restore function, but it may also produce fibrosis. Replacement scar forms where muscle cells have been lost, while broader extracellular-matrix remodeling can alter ventricular shape and stiffness. Persistent injury may lead to chamber dilation, wall thinning, and reduced pumping efficiency. In other patients, residual scar remains despite apparently normal ventricular contraction. The amount and location of damaged tissue, continuing immune activity, and the underlying cause all influence the eventual phenotype.\n\nElectrical instability arises through more than one pathway. Acute inflammation and edema disturb conduction and cellular excitability; later, unevenly distributed scar creates pathways through which electrical impulses can circulate abnormally. Consequently, ventricular arrhythmias may occur during active disease or after biochemical evidence of injury has subsided. Inflammation near the conduction system can cause atrioventricular block. Genetic susceptibility adds another layer: pathogenic variants associated with cardiomyopathy, including some desmosomal disorders, can produce myocarditis-like episodes. In such cases, inflammation and inherited structural vulnerability may interact rather than represent mutually exclusive explanations."
    },
    {
      "heading": "Clinical presentations and major complications",
      "text": "A common presentation is acute chest pain, sometimes following a febrile respiratory or gastrointestinal illness. Pain may resemble that of myocardial infarction, especially when accompanied by elevated cardiac troponin and electrocardiographic changes. If the pericardium is also inflamed, pain may be sharp, vary with breathing, or change with posture. A preceding infection supports a possible infectious context but is neither necessary nor sufficient for diagnosis, and the interval between an infection and cardiac symptoms is variable.\n\nAnother presentation is new or worsening heart failure. Patients may have shortness of breath, reduced exercise tolerance, fatigue, pulmonary congestion, or peripheral fluid accumulation. Left ventricular dysfunction can predominate, but the right ventricle or both ventricles may be affected. Some patients develop symptoms gradually over weeks or months rather than abruptly. In these cases, the clinical problem may initially resemble an otherwise unexplained dilated cardiomyopathy, and the inflammatory origin can remain uncertain without additional testing.\n\nRhythm disturbances form a third major pattern. Palpitations, dizziness, syncope, ventricular tachycardia, or resuscitated cardiac arrest may occur even when overall ventricular function is relatively preserved. Atrioventricular block is particularly relevant in giant-cell myocarditis, cardiac sarcoidosis, and Lyme carditis, although it is not exclusive to these conditions. Atrial fibrillation and other supraventricular arrhythmias may accompany atrial pressure elevation, systemic illness, or direct inflammatory effects.\n\nFulminant myocarditis describes an acute, severe presentation with hemodynamic compromise requiring intensive circulatory support. It is a clinical syndrome rather than a single microscopic diagnosis. Patients may deteriorate rapidly from nonspecific symptoms to severe ventricular dysfunction, hypotension, and cardiogenic shock. Some have a relatively nondilated heart with increased apparent wall thickness caused by edema. The possibility of substantial recovery does not make the initial illness benign; mortality and the need for transplantation remain important, particularly in specific aggressive pathological forms.\n\nOther complications include intracardiac thrombus and systemic embolism when severe ventricular dysfunction causes blood stasis. Persistent dysfunction can produce chronic heart failure, while residual scar can remain a substrate for sudden cardiac death. Symptoms and complication rates vary markedly by age and cause. Infants may have poor feeding, irritability, rapid breathing, or signs of poor perfusion. Immune checkpoint inhibitor-associated disease can present with conduction abnormalities or accompanying muscle weakness, and a normal ejection fraction does not exclude severe illness."
    },
    {
      "heading": "Noninvasive diagnosis and cardiac imaging",
      "text": "The diagnosis of myocarditis begins with a compatible clinical presentation and assessment of plausible alternatives. Medical history includes recent infections, medication exposure, systemic inflammatory disease, family history of cardiomyopathy or sudden death, and relevant travel or epidemiological exposures. Physical examination assesses congestion, perfusion, rhythm abnormalities, and features of associated disease. None of these findings is specific, so clinical suspicion must be supported by objective cardiac testing.\n\nCardiac troponin is a biomarker of myocardial injury, not a myocarditis-specific test. Elevation can support the diagnosis, but a normal value does not exclude all forms or stages of disease. Natriuretic peptides reflect myocardial wall stress and may rise when heart failure is present. Inflammatory markers and the complete blood count can identify systemic inflammation or eosinophilia, but their diagnostic value is limited. Routine viral antibody panels generally cannot establish that a virus is present in, or responsible for inflammation of, the heart.\n\nElectrocardiography may show ST-segment or T-wave abnormalities, sinus tachycardia, ventricular ectopy, conduction delay, or atrioventricular block. Findings can resemble acute coronary occlusion, and a normal tracing does not exclude myocarditis. Echocardiography, an application of ultrasonography, evaluates chamber size, ventricular function, wall motion, pericardial fluid, and hemodynamic consequences. Regional abnormalities can occur, so focal dysfunction alone cannot reliably distinguish myocarditis from ischemic injury.\n\nCardiac magnetic resonance imaging provides noninvasive tissue characterization. The original Lake Louise criteria were published in 2009 and updated in 2018. The updated framework combines at least one T2-based marker of edema with at least one T1-based marker of myocardial injury, such as increased native T1, expanded extracellular volume, or nonischemic late gadolinium enhancement. Characteristic enhancement often involves the subepicardial or mid-wall myocardium rather than the subendocardial distribution typical of infarction. Patterns vary, however, and no single enhancement location proves a particular cause.\n\nMagnetic resonance sensitivity depends on timing, disease distribution, and presentation; it can be less informative in some chronic or predominantly arrhythmic cases. Coronary angiography or coronary computed tomography may be used to exclude obstructive coronary disease when the presentation warrants it. Positron emission tomography has a particular role in evaluating inflammatory activity in suspected cardiac sarcoidosis, with careful preparation needed to suppress normal myocardial glucose uptake. The differential diagnosis also includes pulmonary embolism, stress cardiomyopathy, inherited cardiomyopathies, and noninflammatory causes of myocardial injury."
    },
    {
      "heading": "Endomyocardial biopsy and pathological subtypes",
      "text": "Endomyocardial biopsy obtains small samples of heart muscle through a catheter, usually from the right ventricular septum, although left-sided or combined sampling is used in selected settings. It can establish a tissue diagnosis, identify particular inflammatory patterns, and provide material for immunohistochemistry and molecular testing. Because the procedure is invasive and inflammation may be patchy, it is not performed in every suspected case. Its clinical value is greatest when tissue findings could change treatment or clarify a high-risk presentation.\n\nThe Dallas criteria, introduced in 1986, defined active myocarditis by an inflammatory infiltrate accompanied by adjacent muscle-cell injury or necrosis not typical of ischemic damage. These criteria provided a common research language but have important limitations, including sampling error and variation between observers. Modern histopathology therefore often adds immunohistochemical identification and quantification of inflammatory cells. Molecular assays may detect microbial genomes, but interpretation requires attention to sample quality, viral quantity where relevant, and whether detection plausibly indicates active pathogenic infection.\n\nLymphocytic myocarditis is the most familiar pattern and is often associated with presumed viral or immune-mediated disease. Tissue contains predominantly lymphocytes, with variable macrophages and myocardial injury. The microscopic appearance alone may not identify the initiating cause. Eosinophilic myocarditis contains prominent eosinophils and ranges from relatively limited hypersensitivity-associated inflammation to severe necrotizing disease. Peripheral blood eosinophilia is helpful when present but may be absent, particularly early in the illness.\n\nGiant-cell myocarditis is a rare, aggressive form characterized by extensive inflammatory injury with multinucleated giant cells. It can cause rapidly progressive heart failure, ventricular arrhythmias, and conduction block. Identifying it is particularly consequential because combined immunosuppressive treatment differs from the approach to uncomplicated presumed viral myocarditis. Cardiac sarcoidosis also contains giant cells, but typically within noncaseating granulomas; distinguishing these entities requires the full tissue pattern and clinical context rather than the presence of giant cells alone.\n\nBiopsy is especially relevant in unexplained severe heart failure with hemodynamic compromise, serious ventricular arrhythmias, advanced conduction disease, or suspicion of a treatable specific subtype. Imaging or electroanatomical mapping can sometimes help target abnormal regions and improve diagnostic yield. A negative biopsy does not necessarily exclude disease because a small sample may miss affected tissue. Procedural risks include perforation, tamponade, arrhythmia, and vascular complications, making the balance between diagnostic benefit and procedural risk dependent on the clinical setting and operator experience."
    },
    {
      "heading": "Treatment according to severity and cause",
      "text": "Treatment is organized around hemodynamic stability, ventricular function, rhythm disturbances, and the underlying cause. There is no single therapy appropriate for all myocarditis. A stable patient with chest pain and preserved ventricular function differs substantially from a patient with cardiogenic shock or biopsy-proven giant-cell disease. Much of routine management draws on established treatment for heart failure and arrhythmias, while disease-specific interventions apply to narrower groups.\n\nWhen systolic heart failure persists, standard disease-modifying therapies may include agents acting on the renin–angiotensin–aldosterone system, evidence-based beta blockers, mineralocorticoid receptor antagonists, and sodium–glucose cotransporter 2 inhibitors, according to clinical status and established heart-failure indications. Diuretics relieve congestion but do not directly eliminate myocardial inflammation. In unstable low-output states, the timing and tolerability of chronic heart-failure medicines differ from those in stable patients. Anticoagulation is based on indications such as intracardiac thrombus or atrial fibrillation rather than on myocarditis alone.\n\nFulminant disease may require intensive care, intravenous circulatory support, and temporary mechanical circulatory support. Options include venoarterial extracorporeal membrane oxygenation and selected ventricular-assist devices. These approaches maintain organ perfusion while the myocardium recovers or while decisions about longer-term support or heart transplantation are made. Malignant arrhythmias and conduction block may require cardioversion, antiarrhythmic treatment, or temporary pacing. Permanent device decisions depend partly on whether the electrical disorder persists after the potentially reversible inflammatory phase.\n\nImmunosuppressive treatment is important in selected immune-mediated forms, particularly giant-cell myocarditis and some eosinophilic or systemic autoimmune presentations. Corticosteroids are often combined with other immunosuppressive agents when the pathological subtype warrants it. Immune checkpoint inhibitor-associated myocarditis generally leads to interruption of the implicated treatment and prompt immunosuppressive management within a cardio-oncology framework. By contrast, routine immunosuppression for every patient with presumed viral myocarditis is not supported. The possibility of active infection and the strength of evidence for immune-mediated injury affect treatment selection.\n\nSpecific antimicrobial therapy applies when a treatable pathogen is established, as in Lyme carditis or diphtheria, but routine antiviral treatment for undifferentiated presumed viral myocarditis has no established general role. Intravenous immunoglobulin has been used, especially in pediatric practice, without consistent evidence sufficient to establish universal benefit. Nonsteroidal anti-inflammatory drugs may have a role for associated pericardial pain in selected uncomplicated cases, but they are not disease-modifying treatment for myocardial inflammation and can be problematic in heart failure. Exercise restriction is part of acute management because strenuous exertion during active disease may increase arrhythmic risk."
    },
    {
      "heading": "Recovery, prognosis, and longitudinal assessment",
      "text": "The course of myocarditis varies from complete clinical recovery to chronic ventricular dysfunction, recurrent episodes, transplantation, or death. Prognosis depends on the cause, hemodynamic severity, ventricular involvement, rhythm abnormalities, and tissue damage. Historical statements that divide all cases into fixed proportions of recovery, persistence, and deterioration oversimplify a heterogeneous disease. Outcomes from referral centers, biopsy cohorts, vaccine surveillance, and community chest-pain populations are not interchangeable.\n\nAn uncomplicated chest-pain presentation with preserved ventricular function generally has a more favorable short-term course than cardiogenic shock or sustained ventricular arrhythmia. Nonetheless, symptom resolution does not necessarily mean that all tissue abnormalities have disappeared. Cardiac troponin can normalize before imaging changes resolve, and left ventricular ejection fraction can recover despite residual late gadolinium enhancement. Conversely, persistent symptoms may reflect several processes and cannot by themselves establish continued myocardial inflammation.\n\nImaging findings contribute to risk assessment. Persistent or extensive late gadolinium enhancement, particularly in certain septal or mid-wall distributions, has been associated with adverse outcomes in observational cohorts. Such associations do not yield a precise prognosis for every individual, and their meaning depends on ventricular function, arrhythmias, and the broader clinical context. Repeat echocardiography or magnetic resonance imaging can document recovery or persistent disease, while ambulatory rhythm monitoring can identify abnormalities not captured on a brief electrocardiogram.\n\nReturn to strenuous activity is assessed differently from resumption of ordinary daily activity. Traditional sports-cardiology guidance commonly used a restriction period of three to six months, followed by reassessment of symptoms, ventricular function, biomarkers, and arrhythmias. More recent approaches place greater emphasis on individualized recovery and risk rather than duration alone. These frameworks describe clinical practice rather than a guarantee that a particular elapsed interval eliminates risk. Persistent inflammation, significant ventricular dysfunction, or clinically important arrhythmias alters the assessment.\n\nRecurrent myocarditis raises questions about an unresolved immune-mediated process, repeated exposure, or an underlying inherited cardiomyopathy. A family history of cardiomyopathy or sudden death, recurrent injury episodes, and a suggestive imaging pattern can prompt genetic evaluation in selected cases. Long-term care may include heart-failure follow-up, rhythm surveillance, and cardiac rehabilitation adapted to disease activity and functional recovery. Psychological distress and uncertainty about physical activity can also affect health-related quality of life, even after objective cardiac function improves."
    },
    {
      "heading": "Development of diagnostic standards and current research",
      "text": "The modern understanding of myocarditis developed through pathology, infectious-disease research, experimental immunology, and cardiac imaging. Nineteenth-century descriptions often used inflammatory explanations broadly for heart-muscle disease, before coronary disease and distinct cardiomyopathies were clearly separated. Twentieth-century virology and experimental enterovirus models established that infection could provoke both direct myocardial injury and immune-mediated damage. These models remain influential, although no single animal model reproduces the full diversity of human disease.\n\nThe 1986 Dallas criteria attempted to standardize tissue diagnosis at a time when biopsy interpretation varied substantially. Their limitations became clear as studies showed disagreement between observers and the consequences of patchy sampling. Immunohistochemistry improved characterization of inflammatory infiltrates, while polymerase chain reaction enabled detection of microbial nucleic acids. Each advance also introduced interpretive problems: identifying more inflammatory cells or detecting a viral genome does not automatically establish that a finding explains the patient's illness.\n\nA major treatment landmark was the Myocarditis Treatment Trial, published in 1995. In patients with biopsy-defined myocarditis and impaired ventricular function, the immunosuppressive regimens studied did not produce a clear overall benefit over conventional treatment. The study helped discourage indiscriminate immunosuppression, but it did not settle treatment for every subtype. Later research, including the 2009 TIMIC trial, examined more narrowly defined groups with virus-negative inflammatory cardiomyopathy. These studies illustrate why evidence from one pathological or molecular subgroup cannot simply be generalized to all myocarditis.\n\nNoninvasive imaging broadened recognition beyond the severely ill patients most likely to undergo biopsy. The 2009 and 2018 Lake Louise frameworks provided increasingly structured magnetic resonance criteria, including quantitative mapping techniques. Greater sensitivity also changed the populations labeled as having myocarditis, complicating comparisons with older studies. During the COVID-19 pandemic, large health databases and pharmacovigilance systems further expanded surveillance, while highlighting the importance of consistent case definitions, background rates, and independent review of suspected cases.\n\nCurrent research seeks to distinguish active, treatable inflammation from residual scar; identify patients who benefit from targeted immunomodulation; and clarify interactions between inherited cardiomyopathy and inflammatory injury. Molecular tissue profiling, immune-cell characterization, and improved imaging are being investigated as tools for more precise classification. Important trial-design challenges include the rarity of specific subtypes, spontaneous recovery, variable diagnostic certainty, and selection of meaningful endpoints. Improvements in biomarkers or ventricular function are informative, but their relationship to survival, arrhythmias, functional recovery, and quality of life must be established rather than assumed."
    }
  ],
  "links": [
    "inflammation",
    "incidence",
    "biopsy",
    "coronary-artery-disease",
    "bacteria",
    "autoimmune-disease",
    "systemic-lupus-erythematosus",
    "vasculitis",
    "immune-checkpoint-inhibitor",
    "myasthenia-gravis",
    "covid-19",
    "vaccine",
    "immune-system",
    "edema",
    "t-cell",
    "antibody",
    "fibrosis",
    "chest-pain",
    "shortness-of-breath",
    "fatigue",
    "palpitations",
    "atrial-fibrillation",
    "embolism",
    "diagnosis",
    "medical-history",
    "physical-examination",
    "biomarker",
    "complete-blood-count",
    "ultrasonography",
    "magnetic-resonance-imaging",
    "x-ray-computed-tomography",
    "positron-emission-tomography",
    "differential-diagnosis",
    "histopathology",
    "renin-angiotensin-aldosterone-system",
    "organ-transplantation",
    "corticosteroid",
    "cardiac-rehabilitation",
    "health-related-quality-of-life"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}